Citi Keeps Their Buy Rating on GlaxoSmithKline (GSK)
Citi analyst Peter Verdult maintained a Buy rating on GlaxoSmithKline (GSK – Research Report) today and set a price target of £19.00. The ...
GSK surges 6.5% after $2.2 billion Zantac lawsuits settlement
Shares of GSK rose as much as 6.5% on Thursday after the British drugmaker agreed to pay up to $2.2 billion to settle ...
European stocks slip ahead of US inflation data, GSK jumps
By Paolo Laudani and Sruthi Shankar (Reuters) -European shares slipped on Thursday, with technology and mining stocks leading ...
GSK shares jump after landmark £1.68bn heartburn drug settlement
The pharmaceutical giant has settled the vast majority of cases around its drug Zantac in the US, boosting investor ...
GSK settles vast majority of Zantac claims for $2.2 billion
The British drugmaker reached a $2.2 billion settlement to resolve around 80,000 lawsuits over claims its Zantac heartburn ...
Business Recorder8m
FTSE 100 opens higher on GSK boost
The UK’s benchmark FTSE 100 opened higher on Thursday, led by gains in GSK following the settlement of lawsuits ...